• Press Release

BioMarin Completes Partial Exchange of Convertible Notes Due 2017 for Common Stock

• News Post

Raising a Child with Hemophilia: BioMarin Employee Jess Klass Shares Her Story

• Board Profile

Robert J. Hombach

• Page

Terms of Use – EU (Deutsch)

• Page

Expanded Access

• Board Profile

Barbara Bodem

• Press Release

FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)

• News Post

BioMarin Teams Use Genetic Expertise and Computational Tools to Target More Common Conditions

• News Post

At the Intersection of Science and Art

• News Post

Howard University Partners with BioMarin on Regulatory Fellowship

• News Post

The Unforgettable Moments from ‘The Style Show: A Runway to Empower’

• News Post

The Three Lessons I’ve Learned from Planning a Fashion Show That Are Applicable to Life

• News Post

It’s Time to Give a Platform, or in My Case “Runway,” to People with Rare Disease

• Page

Community Commitment

• Page

Achondroplasia Clinical Trials

• Page

BioMarin Community Guidelines

• Press Release

BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations

• Publication

Study of Intraventricular Cerliponase Alfa for CLN2 Disease

Angela Schulz, M.D., Temitayo Ajayi, M.D., Nicola Specchio, M.D., Ph.D., Emily de Los Reyes, M.D., Paul Gissen, M.B., Ch.B., Ph.D., Douglas Ballon, Ph.D., Jonathan P. Dyke, Ph.D., Heather Cahan, M.D., Peter Slasor, Sc.D., David Jacoby, M.D., Ph.D., and Alfried Kohlschütter, M.D., for the CLN2 Study Group

• Page

Terms of Use – Japan

• Board Profile

Willard H. Dere